2.2.3 This Subscription Agreement has been duly authorized, executed and delivered by the Issuer and, assuming that this Subscription Agreement constitutes a valid and binding obligation of the other parties hereto, is enforceable against the Issuer in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity.
2.2.4 The execution, delivery and performance of this Subscription Agreement (including compliance by the Issuer with all of the provisions hereof), issuance and sale of the Shares and the consummation of the transactions contemplated herein do not and will not (i) conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon, any of the property or assets of the Issuer or any of its subsidiaries, as applicable, pursuant to the terms of any indenture, mortgage, charge, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Issuer or any of its subsidiaries, as applicable, is a party or by which the Issuer or any of its subsidiaries, as applicable, is bound or to which any of the property or assets of the Issuer or any of its subsidiaries, as applicable, is subject, in each case, which would reasonably be expected to have a material adverse effect on the legal authority of the Issuer to enter into and perform its obligations under this Subscription Agreement or have a Company Material Adverse Effect (as defined in the Business Combination Agreement) (an “Issuer Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of the Issuer or any of its subsidiaries, as applicable, or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over the Issuer or any of its subsidiaries, as applicable, or any of their respective properties that would reasonably be expected to have an Issuer Material Adverse Effect.
2.2.5 Except as set forth in the Business Combination Agreement and the other agreements and arrangements referred to therein, as of the date hereof there are no securities or instruments issued by or to which the Issuer is a party containing anti-dilution or similar provisions that will be triggered by the issuance of (i) the Shares, (ii) any Ordinary Shares to be issued pursuant to the Other Subscription Agreements or (iii) any shares of capital stock of the Issuer to be issued pursuant to the other Transactions, in each case, that have not been or will not be validly waived or terminate prior to the Closing Date.
2.2.6 As of the date of this Subscription Agreement, the authorized capital shares of the Issuer consist of (i) 144,460,656 Ordinary Shares, par value NIS 0.01 per share (“Existing Ordinary Shares”), and (ii) 107,943,829 preferred shares, par value NIS 0.01 per share (“Preferred Shares”). As of the date of this Subscription Agreement: (i) 16,518,662 Existing Ordinary Shares are issued and outstanding and (ii) 101,348,311 Preferred Shares are issued and outstanding (consisting of (a) 32,901,384 Series A convertible preferred shares of the Issuer, par value NIS 0.01 per share, (b) 9,957,400 Series B-1 preferred shares of the Issuer, par value NIS 0.01 per share, (c) 18,670,270 Series B-2 preferred shares of the Issuer, par value NIS 0.01 per share, (d) 9,424,937 Series C preferred shares of the Issuer, par value NIS 0.01 per share, (e) 19,313,646 Series D convertible preferred shares of the Issuer, par value NIS 0.01 per share, and (f) 11,080,674 Series E convertible preferred shares of the Issuer, par value NIS 0.01 per share). As of the Closing, the Preferred Shares in (ii) will be converted to Ordinary Shares.
8